Author:
Dabee Smritee,Mugo Nelly,Mudhune Victor,McLellan-Lemal Eleanor,Peacock Sue,O’Connor Siobhan,Njoroge Betty,Nyagol Beatrice,Thurman Andrea R.,Ouma Eunice,Ridzon Renee,Wiener Jeffrey,Haugen Harald S.,Gasper Melanie,Feng Colin,Allen Shannon A.,Doncel Gustavo F.,Jaspan Heather B.,Heffron Renee,Mugo Nelly R.,Mudhune Victor,Heffron Renee,McLellan-Lemal Eleanor,O’Connor Siobhan,Doncel Gustavo F.,Thurman Andrea R.,Njoroge Betty,Nyagol Beatrice,Ouma Eunice,Ndivo Richard,Oguta Maxcine,Opon Haynet,Awili Dorine,Mithika Anne,Chavangi Epines,Oruko Jecinter,Okanda John,Ogendo Arthur,Ayuo Elizabeth,Odipo Evans,Sewe Vitalis,Kerubo Boaz,Mbeda Calvin,Awuonda Eucabeth,Odero Isdorah,Anyango Emily,Mimba Erica,Oloo Fredrick,Odipo Richard,Opollo Valarie,Kerubo Emily,Omondi Fredrick,Gende Angelica,Wandera Kelvin,Juma Carolyne,Were Alice,Ogutu Phoebe,Aremo Susan,Madiega Philister,Ogando Daniel,Arego Judith,Otieno Margaret,Akello Rosemary,Ondeng’e Ken,Omoro Teresa,Amondi Caren,McCarthy Kimberly,Ridzon Renee,Morrison Susan,Krows Meighan,Celum Connie,Ouattara Abenan L.,Yousefieh Nazita,Schwartz Jill,Matthews Allison,Allen Shannon,Russell Elizabeth,Near Karen,Wiener Jeffrey,Samandari Taraz,Deaton Stacie R.,Claypool Lee,Betts Josh E.,Haaland Richard E.,Martin Amy,Fountain Jeffrey,Jacot Terry A.,Erikson David,Blue Steven W.,Jaspan Heather,Dabee Smritee,Feng Colin,Gasper Melanie,Remington Barrett,Frank Bruce L.,Isoherranen Nina,Haugen Harald,Baeten Jared,Thomas Katherine,Kourtis Athena,Tepper Naomi,Ondrejcek Lisa,Williams Angela,Johnson Matt,Jiang Joe,Peacock Sue,Donnell Deborah,
Abstract
AbstractIn a phase-IIa trial, we investigated the influence of 90 days continuous-delivery tenofovir (TFV) intravaginal rings (IVRs) with/without levonorgestrel (LNG) on the genital microbiota of Kenyan women. Eligible women (n = 27; 18–34 years; negative for HIV, sexually transmitted infections, and Amsel-bacterial vaginosis) were randomized 2:2:1 to use of IVRs containing TFV, TFV/LNG, or placebo. Using vaginal wall and IVR swabs at IVR insertion and removal, the genital microbial composition was determined using 16S rRNA gene sequencing. The presence of Candida spp. was determined using qPCR. The vaginal total bacterial burden appeared to decrease with TFV and TFV/LNG IVR use (log100.57 and log100.27 decrease respectively; p > 0.05). The TFV/LNG IVR was more ‘stabilizing’: 50% of the participants’ microbiota community state types remained unchanged and 50% shifted towards higher Lactobacillus abundance. Specifically, TFV/LNG IVR use was accompanied by increased abundances of Lactobacillus gasseri/hominis/johnsonii/taiwanensis (16.3-fold) and L. fermentum/reuteri/vaginalis (7.0-fold; all p < 0.01). A significant shift in the overall microbial α-diversity or β-diversity was not observed for either IVR, and IVR use did not influence Candida spp. prevalence. TFV/LNG and TFV IVRs did not adversely affect the genital microbiota and are safe to use. Our findings support further studies assessing their efficacy in preventing HIV/HSV-2 and unintended pregnancies.
Funder
United States Agency for International Development
Centers for Disease Control and Prevention
Publisher
Springer Science and Business Media LLC